as the preferred first-line agent given its efficacy when dosed appropriately (often required doses >300 mg/day 2 2 http://onlinelibrary.wiley.com/doi/10.1002/ acr.24180/abstract The choice of either allopurinol or febuxostat over probenecid is strongly recommended for patients with moderate-to-severe CKD (stage ≥3). The choice of pegloticase as a first-line therapy is strongly recommended against. Starting treatment with low-dose allopurinol (≤100 mg/day and lower in patients with CKD [stage